This Week in JAMA.
Summary of "This Week in JAMA."
No Summary Available
Affiliation
Journal Details
This article was published in the following journal.
Name: JAMA : the journal of the American Medical Association
ISSN: 1538-3598
Pages: 315
Links
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/22820762
- DOI: http://dx.doi.org/10.1001/jama.2012.3664
Medical and Biotech [MESH] Definitions
Primary Health Care
Care which provides integrated, accessible health care services by clinicians who are accountable for addressing a large majority of personal health care needs, developing a sustained partnership with patients, and practicing in the context of family and community. (JAMA 1995;273(3):192)
Perinatal Mortality
Deaths occurring from the 28th week of GESTATION to the 7th day after birth.
Gestrinone
A non-estrogenic contraceptive which is a weak progestin with strong anti-progesterone properties. It is effective if used once a week orally or can also be used in intravaginal devices.
Puerperal Disorders
Disorders or diseases associated with PUERPERIUM, the six-to-eight-week period immediately after PARTURITION in humans.
Pregnancy Trimester, Third
The last third of a human PREGNANCY, from the beginning of the 29th through the 42nd completed week (197 to 294 days) of gestation.
PubMed Articles
Clinical Trials
Prevention of Contrast Induced Nephropathy in Oncology Patients With Sodium Bicarbonate
Contrast induced nephropathy is a rising cause of acute renal failure in all patients. A study published in JAMA 2004, show a superiority of a hydratation with sodium bicarbonate in compar...
Prevention of Contrast Induced Nephropathy With Sodium Bicarbonate
Deterioration of kidney renal function occurs in a minority of people due to contrast-required procedures. The purpose of this study is to compare two different interventions to reduce the...
Dose Response Study in Japanese Patients
This is a 12-week study to determine the effect on glucose and lipids, safety, and tolerability of four doses of tesaglitazar (0.25, 0.5, 0.75 and 1 mg) compared with placebo in patients w...
An Open Parallel Study to Determine the Optimum Dosing Schedule for AS-101 in AIDS/ARC Patients
To compare AS-101 dosing schedules (once a week; 3 times a week; 5 times a week; or 5 times per week on alternate weeks) on the effect on clinical immunology and virus burden in AIDS or A...
GALLANT 7 Tesaglitazar Add-on to Sulphonylurea
This is a 24-week randomized double-blind, parallel-group, multi-center, placebo-controlled study of tesaglitazar (0.5 mg and 1 mg) given as add-on therapy to sulphonylurea in patients wit...
